1MK Stock Overview A medical device company, manufactures and sells medical devices in Europe and internationally. More details
Rewards Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Mauna Kea Technologies SA Competitors Price History & Performance
Summary of share price highs, lows and changes for Mauna Kea Technologies Historical stock prices Current Share Price €0.14 52 Week High €0.49 52 Week Low €0.13 Beta 1.37 1 Month Change -2.51% 3 Month Change -55.91% 1 Year Change -68.29% 3 Year Change -79.10% 5 Year Change -90.70% Change since IPO -95.60%
Recent News & Updates
Mauna Kea Technologies Announces New Positive Clinical Results for Cellvizio in Food Intolerance Oct 17
First half 2024 earnings released Oct 17
Mauna Kea Technologies Sa Reaffirms Sales Guidance for the Year 2024 Oct 16
Mauna Kea Technologies Announces Positive Clinical Results in Lung Cancer Obtains with Cellvizio Sep 16
Mauna Kea Technologies SA to Report First Half, 2024 Results on Oct 30, 2024 Jul 26
Mauna Kea Technologies SA to Report First Half, 2024 Results on Oct 02, 2024 Jun 13 See more updates
Mauna Kea Technologies Announces New Positive Clinical Results for Cellvizio in Food Intolerance Oct 17
First half 2024 earnings released Oct 17
Mauna Kea Technologies Sa Reaffirms Sales Guidance for the Year 2024 Oct 16
Mauna Kea Technologies Announces Positive Clinical Results in Lung Cancer Obtains with Cellvizio Sep 16
Mauna Kea Technologies SA to Report First Half, 2024 Results on Oct 30, 2024 Jul 26
Mauna Kea Technologies SA to Report First Half, 2024 Results on Oct 02, 2024 Jun 13
New major risk - Negative shareholders equity May 03
Mauna Kea Technologies SA Provides Sales Guidance for the Year 2024 Apr 27
New minor risk - Financial data availability Apr 15 Mauna Kea Technologies SA, Annual General Meeting, Jun 06, 2024
Insufficient new directors Jan 01
Mauna Kea Technologies SA ADR - Sponsored to Be Deleted from OTC Equity Dec 22
New major risk - Share price stability Nov 28 Mauna Kea Technologies SA announced that it expects to receive €6 million in funding from Telix Pharmaceuticals Limited Nov 14
Mauna Kea Technologies Announces First Patient Enrolled in the Pivotal CLEVER Clinical Trial in Peripheral Lung Cancer Nov 02
No longer forecast to breakeven Oct 25
New major risk - Revenue and earnings growth Oct 25
New minor risk - Share price stability Oct 03
First half 2023 earnings released: EPS: €0.063 (vs €0.14 loss in 1H 2022) Oct 02
New major risk - Revenue and earnings growth Sep 29
Mauna Kea Technologies and Endoscopy Institute of Hawaii Achieve 1,200 Procedure Milestone Sep 19
No longer forecast to breakeven Sep 06 Mauna Kea Technologies Appoints Côme de La Tour du Pin as its Chief Financial Officer Mauna Kea Technologies Announces Start of Enrollment in Peripheral Lung Cancer Multi-Site Clinical Trial Combining Ion® with Cellvizio® Mauna Kea Technologies SA to Report First Half, 2023 Results on Sep 28, 2023
Mauna Kea Technologies SA Announces the Publication of Results of the First in Human Clinical Study Combining Robotic-Assisted Bronchoscopy and Needle-Based Confocal Laser Endomicroscopy for Lung Cancer Jan 13
No longer forecast to breakeven Nov 16
Mauna Kea Technologies SA Announces Success of Clinical Trial on Prediction of Remission in Patients with Inflammatory Bowel Disease (IBD) and its Publication in Gastroenterology Nov 01
Mauna Kea Technologies SA Announces the Appointment of Sacha Loiseau as Chief Executive Officer Oct 05
Mauna Kea Technologies SA to Report First Half, 2022 Final Results on Oct 20, 2022 Sep 16
Mauna Kea Technologies SA to Report First Half, 2022 Results on Oct 20, 2022 Sep 14
No longer forecast to breakeven Apr 27
No longer forecast to breakeven Apr 23
Mauna Kea Technologies Announces First of Its Kind U.S. FDA 510(k) Clearance for Use of Cellvizio in a New Category of Molecular Imaging-guided Endoscopic, Laparoscopic, Needle-Based Procedures Apr 13
Mauna Kea Technologies SA Announces Start of Enrollment in Peripheral Lung Cancer Multi-Center Clinical Trial Feb 24
Mauna Kea Technologies SA announced that it has received $12.8 million in funding from Lightspeed China Partners, Qiming Weichuang Venture Capital Management (Shanghai) Company Limited, Shanghai Ivy Investment Holdings Co., Ltd. Jan 07
First half 2021 earnings released Sep 26
Mauna Kea Technologies Receives U.S. FDA 510(k) Clearance of its Next-Generation Cellvizio® Platform Combined with a Fluorescent Contrast Agent Aug 25
Mauna Kea Technologies SA Provides Earnings Guidance for the Twelve Months Ending December 31, 2021 Jul 24
Mauna Kea Technologies Unveils Its Next-Generation Cellvizio® Platform Jun 15
Full year 2020 earnings released May 09
Mauna Kea Technologies: Cellvizio® Combined with Artificial Intelligence Outperforms Standard of Care for Pancreatic Cyst Diagnosis and Risk Stratification Feb 10
New 90-day high: €1.55 Jan 09 Mauna Kea Technologies SA to Report Q2, 2021 Results on Jul 22, 2021
Mauna Kea Technologies Announces Board Changes Dec 19
Telix Pharmaceuticals Limited and Mauna Kea Technologies Announces Exclusive Scientific and Clinical Research Collaboration Dec 17
New 90-day low: €1.00 Oct 31
New 90-day high: €1.51 Oct 12
New 90-day low: €1.04 Sep 23
New 90-day low - €1.14 Sep 03 Shareholder Returns 1MK DE Medical Equipment DE Market 7D -4.2% -1.6% 0.3% 1Y -68.3% -9.1% 6.9%
See full shareholder returns
Return vs Market: 1MK underperformed the German Market which returned 7.2% over the past year.
Price Volatility Is 1MK's price volatile compared to industry and market? 1MK volatility 1MK Average Weekly Movement 15.4% Medical Equipment Industry Average Movement 6.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 1MK's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1MK's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Mauna Kea Technologies SA, a medical device company, manufactures and sells medical devices in Europe and internationally. It offers range of medical devices in gastroenterology, pulmonology, and urology areas. Its product portfolio includes Cellvizio, a real-time in vivo cellular imaging platform which enables physicians to monitor progression of disease over time, assess point-in-time reactions, classify indeterminate areas, and guide surgical interventions.
Show more Mauna Kea Technologies SA Fundamentals Summary How do Mauna Kea Technologies's earnings and revenue compare to its market cap? 1MK fundamental statistics Market cap €10.60m Earnings (TTM ) -€11.21m Revenue (TTM ) €8.16m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 1MK income statement (TTM ) Revenue €8.16m Cost of Revenue €2.25m Gross Profit €5.91m Other Expenses €17.12m Earnings -€11.21m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.17 Gross Margin 72.42% Net Profit Margin -137.49% Debt/Equity Ratio -137.6%
How did 1MK perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/30 20:19 End of Day Share Price 2024/12/30 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Mauna Kea Technologies SA is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Guillaume Cuvillier Gilbert Dupont Stephanie Lefebvre Gilbert Dupont Sachin Soni Kempen & Co. NV
Show 3 more analysts 
